Table 4 Current extracellular vesicles based clinical trials for common diseases
From: Extracellular vesicles as tools and targets in therapy for diseases
S.No. | Disease | Type | EVs as a therapeutic target | Origin of EVs in clinical Use | Phase, patients | NCT | Refs. |
|---|---|---|---|---|---|---|---|
1 | HNSCC | HNSCC |  | Grapes | P = 1,N = 60 | NCT01668849 | |
OSCC | Blood EVs | Metformin hydrochloride increases EVs | P = NA, N = 30 | NCT02147418 | |||
Oral Mucositis Associated With Chemoradiation Treatment |  |  | P = 1, N = 9 | NCT03109873 |  | ||
2 | Gastric Cancer |  | Circulating Exosomes |  | N = 80 | NCT01779583 | |
|  | Hsp70 carrying EVs |  | P = NA N = 71 | NCT02662621 | |||
Ulcers (wound healing) | Plasma |  | P = 1, N = 5 | NCT02565264 | |||
3 | Breast cancer |  | Detect EV induced Hypoxia |  | N = 21 | NCT03262311 | |
|  | Rosuvastatin reduces TFs |  | P = 2,N = 20 | NCT01299038 | |||
4 | Lung cancer | Non-small-cell lung cancer lung metastases | Circulating EVs | DC | P = 2, N = 42 | NCT01159288 NCT03108677 | |
|  | RNA |  | P = NA, N = 90 | NCT03108677 | |||
|  | Liver caner | Advanced hepatocellular carcinoma and liver metastasis |  |  | P = 1, N = 9 |  | |
5 | Neurodegenerative disorders | Alzheimer’s disease Hypoxia-ischemia |  | MSC MSC | P = 1/2, N = 10 | ||
Acute ischemic stroke |  | MSC | N = 300 | ||||
| Â | Â | MSC | NA | ||||
6 | Cardiovascular Diseases | Cerebrovascular disorders |  | MSC | P = 1, | ||
Acute ischemic stroke |  | MSC | P = ½, N = 5 | ||||
7 | Diabetes | Insulin resistance T1DM T1DM T2D |  | Ginger MSCs Serum Serum | NA P = 2/3, N = 20 N = 20 N = 200 | ||
8 | Renal Disease | Chronic kidney diseases |  | UC | P = 1, N = 20 |  | |
9 | Autoimmune diseases | Osteoarthritis Sepsis |  | MSC DC | P = 1 N = 50 | ||
10 | Viral Infection | COVID-19 COVID-19 |  | UC MSC | P = 2, N = 100 P = 2/3,N = 300 | NCT04288102 NCT04392778 |
